VIP (Vasoactive Intestinal Peptide): Clinical Guide for Prescribing Practices
VIP (Vasoactive Intestinal Peptide) is a 28-amino acid neuropeptide with potent anti-inflammatory, immunomodulatory, and vasodilatory properties. It is central to the Shoemaker protocol for Chronic Inflammatory Response Syndrome (CIRS) and mold illness, where it serves as the final intervention to restore neuroimmune regulation after other markers are corrected.
Also Known As
How VIP (Vasoactive Intestinal Peptide) Works
VIP binds VPAC1 and VPAC2 receptors on immune cells, activating adenylyl cyclase and increasing intracellular cAMP, which suppresses NF-kB mediated transcription of pro-inflammatory cytokines (TNF-alpha, IL-6, IL-12) while upregulating anti-inflammatory IL-10 production [2]. In pulmonary vasculature, VIP activates endothelial nitric oxide synthase, producing vasodilation and reducing pulmonary artery pressure [3]. It also stabilizes mast cells, reduces TGF-beta1 driven fibrosis, and promotes regulatory T-cell differentiation [4], providing multi-level control of the chronic inflammatory response seen in CIRS [1].
Clinical Evidence
The Shoemaker protocol clinical data demonstrates significant improvement in CIRS biomarkers (TGF-beta1, MMP-9, VEGF, MSH) and pulmonary artery systolic pressure following intranasal VIP administration [1]. A 2010 study documented reduction of pulmonary artery pressure from 35 to 25 mmHg in CIRS patients after VIP therapy [1]. Phase II clinical trials of IV VIP (Aviptadil/Zyesami) for COVID-19 ARDS demonstrated improved oxygenation and reduced ICU mortality in a 196-patient trial [3]. Preclinical evidence for anti-inflammatory and immunoregulatory properties spans over 40 years of published research [2].
Clinical Uses
Patient Selection and Screening
Primary candidates are patients with confirmed CIRS per Shoemaker diagnostic criteria who have completed prerequisite interventions (cholestyramine binding, MARCoNS eradication, normalization of inflammatory markers) [1]. Also appropriate for patients with documented elevated pulmonary artery systolic pressure related to chronic inflammation. Do not initiate VIP before MARCoNS is cleared, as VIP may promote nasal biofilm growth [1]. Screen for pancreatic sensitivity (VIP stimulates exocrine pancreatic function) and hypotension risk [2]. Not appropriate as a first-line or standalone anti-inflammatory agent.
Dosing and Administration
Intranasal administration: 50 mcg per spray, typically 1 spray in each nostril 4 times daily (total 400 mcg per day) [1]. Initiate at lower dose (1 spray twice daily) and titrate up over 1 to 2 weeks to assess tolerability. Treatment duration is typically 30 to 90 days with serial biomarker monitoring at 30-day intervals [1]. Monitor lipase at baseline and every 2 weeks during initial treatment. Blood pressure should be checked before and after first dose. Discontinue and reassess if lipase rises above 2x upper limit of normal.
Route: Intranasal spray, intravenous infusion
Protocol notes: Administered as intranasal spray (50mcg per spray, typically 4 sprays per day). In the Shoemaker protocol, VIP is initiated only after other CIRS markers (MARCoNS, TGF-beta1, MMP-9) are addressed. IV formulations (Aviptadil) have been studied for pulmonary indications.
Side Effects and Monitoring
Clinical Considerations
Practice Economics
VIP serves as the capstone intervention in CIRS programs, making it relevant only for practices with established mold illness and environmental medicine protocols [1]. Patient acquisition cost is lower since VIP candidates have already completed the multi-step CIRS workup within the practice. The extensive monitoring requirements (serial labs, echocardiography) generate significant ancillary testing revenue. Practices specializing in CIRS report that the full protocol (from initial evaluation through VIP completion) represents 6 to 12 months of continuous patient engagement.
FDA Category Status
Compounding eligibility varies; verify current FDA status before prescribing
FDA bulk drug substance category determines compounding eligibility. Category designations are subject to change; always verify the current status before prescribing. This information is provided for clinical reference and does not constitute legal or regulatory advice.
Pharmacy Integrations
Prescribe VIP (Vasoactive Intestinal Peptide) through Karpa's integrated compounding pharmacy network with one-click ordering and direct-to-patient fulfillment.
Frequently Asked Questions
When is VIP indicated in CIRS treatment and why is sequencing important?
What biomarkers should be monitored with VIP therapy?
Which patient populations are appropriate candidates for VIP?
References
- Shoemaker RC, et al. Vasoactive intestinal polypeptide (VIP) corrects chronic inflammatory response syndrome (CIRS) acquired following exposure to water-damaged buildings. Health. 2013;5(3):396-401.
- Delgado M, et al. Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions. Amino Acids. 2013;45(1):25-39.
- Youssef J, et al. IV aviptadil (VIP) for COVID-19 respiratory failure: results of a prospective trial. Crit Care Med. 2022;50(1):e40-e49.
- Leceta J, et al. Vasoactive intestinal peptide regulates Th17 function in autoimmune inflammation. Neuroimmunomodulation. 2007;14(3-4):134-138.
Related Peptides in Immune Support
Disclaimer: This information is intended for licensed healthcare providers only and does not constitute medical, legal, or regulatory advice. Clinical decisions should be based on your professional judgment, current evidence, and applicable state and federal regulations. Always verify FDA category status and compounding eligibility before prescribing. Content is reviewed periodically but may not reflect the most recent regulatory changes.
Prescribe VIP (Vasoactive Intestinal Peptide) Through Karpa
Streamline your peptide prescribing workflow with integrated pharmacy ordering, patient tracking, and compliance documentation.
Prescribe VIP (Vasoactive Intestinal Peptide) Through Karpa